Eukaryotic Translation Initiation Actors (eifs) as Novel Biomarkers in Head and Neck Squamous Cell Carcinoma (hnscc)

Simple SummaryContent extracted from patent full text and abstract with AI.

This invention describes the use of specific eukaryotic translation initiation factors (eIFs) and their kinases as novel biomarkers for Head and Neck Squamous Cell Carcinoma (HNSCC). By measuring the levels of these proteins or their mRNAs in biological samples, clinicians can diagnose HNSCC and provide survival prognoses for patients. The invention also covers kits for such detection, and therapeutic strategies that involve targeting these factors to treat HNSCC.

Use CasesContent extracted from patent full text and abstract with AI.

• Early and accurate diagnosis of HNSCC by detecting eIFs and/or their kinases in tissue or body fluids (such as blood or saliva).
• Assessment of survival prognosis for HNSCC patients, helping guide treatment decisions.
• Monitoring treatment response or disease progression in HNSCC using biomarker levels.
• Developing point-of-care diagnostic kits for rapid, on-site evaluation of HNSCC risk or status.
• Therapeutic applications: using eIF-modulating compounds to inhibit tumor growth, alone or in combination with other cancer therapies.

BenefitsContent extracted from patent full text and abstract with AI.

• Enables more precise and earlier detection of HNSCC compared to current diagnostic approaches.
• Allows personalized prognosis, helping tailor therapies to individual patient risk.
• Kits may be suitable for non-invasive or minimally invasive testing (e.g., blood or saliva), increasing patient compliance and speed of diagnosis.
• Potential to improve patient outcomes by enabling earlier intervention and better monitoring of disease.
• Therapeutic targeting of these eIFs provides a novel approach for treating a genetically heterogeneous cancer, potentially overcoming resistance to other treatments.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention relates to a method of diagnosing Head and Neck Squamous Cell Carcinoma (HNSCC) in an individual. In addition, the present invention relates to a method of providing a survival prognosis to an individual suffering from Head and Neck Squamous Cell Carcinoma (HNSCC). Moreover, the present invention relates to a kit for performing the above-mentioned methods.